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Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factorkappa B (NF-κB) pathway
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Background/aim: Lycopene is associated with anticancer effects in various tumor types. However, the exact underlying mechanisms of
action of lycopene in human cervical cancer remain to be determined. This study aimed to determine anticancer efficacy and mechanism
of lycopene in human cervical carcinoma (HeLa) cells.
Materials and methods: HeLa cells were treated with cisplatin (1 µM) alone, lycopene (10 µM) alone, and in combination for 72 h. The
cell viability of HeLa cells was assessed via MTS assay. Western blot was used to analyze the expression levels of the nuclear factor-kappa
B (NF-κB), B-cell-associated X protein (Bax), nuclear factor erythroid 2-related factor (Nrf2), and B-cell lymphoma 2 (Bcl-2).
Results: We found that lycopene acts as a synergistic agent with cisplatin in preventing the growth of HeLa cells. The rates of HeLa cells’
viability were 65.6% and 71.1% with lycopene and cisplatin treatment alone compared to the control group, respectively (P < 0.001).
The inhibitory effect of cisplatin was enhanced with lycopene addition by declining the cell viability to 37.4% (P < 0.0001). Lycopene
treatment significantly increased Bax expression (P < 0.0001) and decreased Bcl-2 expression (P < 0.0001) in HeLa cells. Furthermore,
lycopene markedly activated the Nrf2 expression (P < 0.001) and suppressed the NF-κB signaling pathway (P < 0.0001).
Conclusion: Lycopene increases the sensitization of cervical cancer cells to cisplatin via inhibition of cell viability, up-regulation of
Bax expression, and down-regulation of Bcl-2 expression. Furthermore, the anticancer effect of lycopene might be also associated with
suppression of NF-κB-mediated inflammatory responses, and modulation of Nrf2-mediated oxidative stress. The results of the present
study suggest that lycopene and concurrent cisplatin chemotherapy might have a role in improving the treatment of cervical cancer.
Key words: Lycopene, cervix cancer, cancer treatment, chemotherapy

1. Introduction
Cervical cancer is ranked as the third most frequent
gynecological cancer in the United States and the mortality
rate is high [1]. Fortunately, the incidence of cervical cancer
has decreased as a result of cytological screening (e.g., the
Pap smear test), DNA testing for carcinogenic human
papillomavirus (HPV) types, and HPV vaccination [2].
However, cervical cancer remains a major problem, with an
estimated 569,000 new cancer cases worldwide and 311,000
deaths in 2018 [3]. Current treatment options of cervical
cancer include chemotherapy, surgery, and radiotherapy
that can be used either alone or in combination. Cisplatinbased combination therapy is the most commonly used
chemotherapeutic regimen for advanced carcinomas of
the cervix [4]. Nevertheless, common side effects and
chemotherapy resistance development significantly impair
the effectiveness of cisplatin in the treatment of advanced
carcinomas of the cervix [5].

The development of drug resistance remains a major
barrier to cancer treatment. Although the molecular
basis for cancer therapy resistance is not well known,
various molecular pathways are considered to play a role.
Previous studies have shown that the nuclear factor kappa
B (NF-κB) transcription factor is a vital mechanism of
chemotherapy resistance [6]. Activation of NF-κB leads to
the enhancement of cell proliferation and up-regulation
of antiapoptotic genes, both of which contribute to
carcinogenesis [7]. Elevated NF-κB activity is a common
phenomenon in many types of cancer, notably in cervical
cancer [8]. NF-κB also plays a significant role in the
progress of platinum-based chemotherapy resistance,
such as cisplatin. As a result, NF-κB was considered to be
a possible target for current therapies, particularly as an
adjuvant to overcome platinum-containing chemotherapy
resistance [9]. Another transcription factor, nuclear factor
erythroid 2-related factor 2 (Nrf2), plays a critical role in
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the antioxidative process [10]. Lee et al. suggested that
Nrf2 enhances the expression of various antioxidants
and detoxification enzymes that play a central role in
the mitigation of oxidative stress [11]. Ben-Neriah et al.
showed that a wide range of diseases such as autoimmune
disorders, neurodegeneration, and cancer was associated
with a disparity between Nrf2 and NF-κB pathways [12].
The simultaneous activation and inactivation of Nrf2 and
NF-κB are considered novel targets of chemopreventive
agents [10].
Nutritional factors are widely accepted to be critical in
carcinogenesis. Carotenoids are pigments found naturally
in the most red-orange-colored fruits and vegetables
[13]. Lycopene has been a widely used carotenoid with
an unsaturated hydrocarbon chain that can function as
an antioxidant [14]. Besides its antioxidant properties,
lycopene has been reported to exhibit anticarcinogenic,
antiinflammatory, and cardioprotective activities [15].
The anticancer potential of lycopene against certain types
of cancer has been shown, including prostate, pancreatic,
and breast cancer [16–18]. Although the main anticancer
mechanism of lycopene has not been elucidated, it
is shown that lycopene induces apoptosis via downregulation of antiapoptotic protein Bcl-2, up-regulation
of the proapoptotic proteins Bim, Bax, and Bid proteins
and caspase activation [19]. Furthermore, lycopene has
been shown to suppress the NF-κB transcription factor,
which plays a pivotal role in the regulation of apoptosis in
pancreatic, prostate, and breast cancer cell lines [18,20].
However, there is no previous study on the influences
of lycopene on human cervical carcinoma (HeLa) cells
and the corresponding mechanism. Therefore, this study
aimed to assess the synergistic mechanism of cisplatin
and lycopene and the anticancer properties of lycopene
on cervical cancer HeLa cells through evaluating its effect
on proliferation, apoptosis, and inflammatory signaling
pathways, namely NF-κB and Nrf2.
2. Materials and methods
2.1. Cell culture and reagents
A HeLa cervical cancer cell line was obtained from the
American Type Culture Collection (Manassas, VA, USA).
Cisplatin was supplied by Sigma (St. Louis, MO, USA)
and lycopene was provided by DSM Nutrition (İstanbul,
Turkey). HeLa cells were grown and maintained in an
appropriate RPMI-1640 medium supplemented with
10% fetal bovine serum, 100 µg/mL streptomycin, 2 mM
L-glutamine, and 100 U/mL penicillin G. Cell incubation
was performed at 37 °C in a humidified incubator with
an atmosphere containing 5% CO2. No growth factor has
been added to the media of the cell culture. In phosphatebuffered saline (PBS), cisplatin was dissolved to form a 1
mM stock solution and final working concentrations.

2.2. Treatment protocol and cell viability assay
A 3- (4,5-dimethylthiazol-2-yl) -5- (3-carboxymethoxyphenyl)
-2- (4-sulfophenyl) -2H-tetrazolium (MTS) colorimetric
assay was used to determine the viability of cells. In brief,
cells were seeded in 96-well plates at a concentration of 104
cells per well and incubated overnight to allow cells to attach.
After incubation, the cells were treated with lycopene alone
(10 µM), cisplatin alone (1 µM), and in combination for 72 h.
The cells were incubated at 37 °C in 5% CO2 for 2 h after 72 h
of total treatment. For assay a 1 mg/mL MTS reagent (Sigma,
St. Louis, MO, USA) was added to each well. The absorbance
of the solution was estimated using a microplate reader
(BioTek Instruments, Winooski, VT, USA) at 490 nm. The
sample readings were calculated by subtracting the mean of
background absorbances. Viability was calculated concerning
control cells (%). MTS assay was performed at least four
times.
2.3. Western blot analysis
The HeLa cell extracts were obtained with PBS-1%
TritonX-100 (Sigma) containing a lysis buffer, and 20 µg
of protein preparation was loaded onto 10% acrylamide
gels in each lane. Proteins in samples were fractionated
by electrophoresis and migrated on 10% SDS-PAGE, then
transferred to a nitrocellulose membrane. Blocking was
carried out using 5% dry milk for 2 h. Then, membranes were
incubated overnight with diluted (1:1000) primary antibody,
anti-Nrf2, anti-Bcl-2, anti-Bax, and anti-NF-κB p65 (Santa
Cruz, CA, USA) at 40 °C. Antibody labeling was detected
by incubation with a secondary antibody (HRP-linked goat
antimouse IgG, Abcam, Cambridge, UK). A monoclonal
mouse β-actin antibody (A5316, Sigma) was used to control
the loading of protein. Band quantification analysis was done
using ImageJ software (NIH, Bethesda, USA). Standardization
of results was achieved using the β-actin expression as a
percentage of control in each group. Blots were performed in
triplicate to confirm the reproducibility of data.
2.4. Statistical analysis
All measures were presented as group mean ± SD, which were
replicated four times. Experimental data were carried out
with one-way ANOVA using the General Linear Model (SPSS
version 23.0, Chicago, IL, USA). Tukey’s post hoc test was
applied to clarify group mean changes. Statistical significance
defined as P < 0.05 was indicated by a number sign (#). In
addition, P < 0.01 and P < 0.001 were marked with 2 (##)
and 3 (###) number signs, respectively, compared to the
control group in the figures. GraphPad Prism 7.0 (GraphPad
Software) was used for data graphing.
3. Results
3.1. Lycopene enhances the growth inhibitory effect of
cisplatin on the proliferation of HeLa cells
The effects of treatment of lycopene (10 µM), cisplatin
(1 µM), and the combination of both for 72 h on the
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viability of HeLa cervical carcinoma cells were measured
through MTS assay. MTS analysis presented that lycopene
and cisplatin treatment alone decreased the viability of
HeLa cells to 65.6% and 71.1%, respectively (P < 0.001,
Figure 1). When cells were treated in combination with
lycopene and cisplatin, lycopene improved the inhibitory
effect of cisplatin by declining the cell viability to 37.4%
compared to the control group (P < 0.0001, Figure 1). The
combination treatment with cisplatin and lycopene was
found to be more efficient than cisplatin and lycopene
alone treatment to inhibit cell growth at 72 h in HeLa cells.
Above all, these results indicate that lycopene increases the
sensitivity of HeLa cells to cisplatin.
3.2. Lycopene sensitizes HeLa cells to cisplatin-induced
apoptosis markers
To evaluate the possible mechanism responsible for the
anticancer effects of lycopene, we investigated whether
cisplatin in combination with lycopene induced more
apoptosis than either agent alone. HeLa cells treated with
lycopene (10 µM), cisplatin (1 µM), and combination of
both for 72 h and apoptosis-related proteins Bcl-2 and
Bax levels were analyzed by western blotting. Lycopene
and concurrent cisplatin chemotherapy enhanced the
cisplatin-induced properties by reducing the antiapoptotic
Bcl-2 protein (P < 0.0001, Figure 2A) and increasing
proapoptotic Bax levels (P < 0.0001, Figure 2B) compared
to cisplatin-only treated cells.
3.3. Lycopene suppresses NF-κB activation and induces
Nrf2 activation in HeLa cells
The level of Nrf2 was significantly reduced in the cisplatinonly treated HeLa cells compared with those expressed in
the control HeLa cells. It was found that lycopene increased
Nrf2 expression in lycopene-only treated cells compared
to control cells. The combination group had a significantly
higher Nrf2 level than the cisplatin-only treated cells
group (P < 0.001, Figure 2C). Lycopene decreased NFκB activation, which is increased by cisplatin in HeLa
cells. As shown in Figure 2D, cisplatin-only treated cells
had increased the NF-κB p65 level, while lycopene-only
treated cells had reduced this protein compared to control.
The NF-κB p65 expression level was further reduced by
adding lycopene to cisplatin only treated cell group (P <
0.0001).
4. Discussion
Chemoprevention is considered one of the most
mentioned factors in combating cancer. Lycopene, other
than being a color pigment naturally available in tomatoes,
is proven to drastically decrease the risk of cancer thanks
to epidemiologic and cell culture studies. Even though the
anticarcinogenic activity and structure of lycopene have
been studied therapeutically on many types of tumors,
its impact on cervical cancer, a condition with a high
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Figure 1. The effects of lycopene treatment on the proliferation
of HeLa cell lines. The data are described as having cell viability
relative to vehicle control of treated cell and shown as mean ± SD
of four independent experiments (ANOVA and Tukey’s post hoc
test statistical significance between groups is shown by # P < 0.05,
## P < 0.01, ### P < 0.001, #### P < 0.0001 compared as control
group; *** P < 0.001, **** P < 0.0001 shows comparison between
each treatment group, and ns means not significant.).

mortality rate on women, has yet to be fully understood.
In the current study, we determined whether lycopene
alone will show an effect on HeLa cells, and by which
mechanism and how it will affect the action of cisplatin,
one of the most frequently used chemotherapeutic drugs
in cervical cancer. The mechanism of the inhibitory
effect of lycopene on HeLa cells was investigated at the
molecular level by determining Bcl-2, Bax, NF-κB, and
Nrf2 protein expression levels. To our knowledge, this is
the first research to evaluate the role of lycopene in Nrf2
and NF-κB pathways in a human cervical cancer cell line
(HeLa).
Apoptosis can be defined as biochemical and
morphological cellular changes that occur via caspasemediated pathways in response to various fatal stimuli.
On the other hand, cancerous cells can become resistant
to apoptosis through a wide range of mechanisms. There
are two main apoptotic pathways, named extrinsic
and intrinsic, which are responsible for carcinogenesis
regulation [21]. The intrinsic pathway is activated through
the decomposition of the mitochondrial membrane and
the release of cytochrome c that functions in the activation
of caspase-9 [22]. Mitochondrial membrane stabilization
is ensured through proapoptotic (Bcl-XL and Bcl-2) and
antiapoptotic Bcl-2 (Bax, Bim, and Bid) family members
with different functions [23]. Many reports have presented
that lycopene induces apoptosis by activating the intrinsic
pathway [24,25]. In a study conducted by Sahin et al., it
was shown that the risk of chemically-induced breast
cancer was decreased in rats in vivo through treatment
with a lycopene and genistein combination that ensured
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Figure 2. The effects of lycopene treatment on the levels of Bcl-2 (A), Bax (B), Nrf2 (C), and NF-κB (D) protein expression as detected
by Western blotting analysis of HeLa cells. The band intensities were measured using densitometric analysis. The data were presented as
a ratio of treatment value to control value set at 100%. The bar represents the mean and standard error of the mean. Western blots were
repeated at least four times. β-actin was used as a loading control protein for Western blotting analysis (ANOVA and Tukey’s post hoc
test statistical significance between groups is shown by # P < 0.05, ## P < 0.01, ### P < 0.001, #### P < 0.0001 relative to control group;
*** P < 0.001, **** P < 0.0001 shows comparison between each treatment group).

a reduction of Bcl-2 and an increase in Bax proteins
[24]. Application of lycopene to hormone-refractory
prostate cancer cell lines in a dose-dependent manner has
resulted in a decrease of Bcl-2 expression, an increase in
Bax proteins, and induction of apoptosis by causing cycle
distribution changes [25]. Similar to these findings, our
results showed that lycopene treatment, in addition to
cisplatin, led to a decreased Bcl-2 level and an increased

Bax level, suggesting that lycopene enhances the potency
of cisplatin by affecting apoptosis-related protein levels on
HeLa cells. It is quite likely in the future to monitor drastic
changes in many tumors by inducing apoptosis through
the intrinsic pathway with lycopene and anticancer drugs.
NF-κB undertakes the role of a bridge between
inflammation and cancer together with the regulation of
genes that have functions in immunity, inflammation, and
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tumor development as a transcription factor [12]. Under
normal circumstances, NF-κB is available in an inactive
form and attached to IκBα within the cellular cytoplasm.
Phosphorylation of IκBα by varying stimuli leads to the
activation of NF-κB. However, NF-κB remains constantly
active in a cancerous cell by inducing the expression of
the apoptosis-inhibiting genes such as cIAP1, cIAP2, and
survivin, and leads to uncontrolled cellular growth [26,27].
Lycopene treatment decreases RAS-dependent activation of
NF-κB, regulating the effects of the cell cycle and apoptosisrelated proteins such as cyclin D1, p21, p27, Bax, and Bcl2 [28]. It was found that combination treatment of ursolic
acid, an NF-κB inhibitor, with taxane and cisplatin in HeLa
cells decreased the dose of chemotherapy drugs required
to produce the same effect and resulted in a synergistic
increase in the formation of chemotherapy agent-induced
apoptosis [29]. Lycopene has been monitored to decrease
the expression of prosurvival genes by causing NF-κB
inhibition in pancreatic cancerous cells [18]. Additionally,
lycopene decreases the invasiveness of human hepatoma
cells by reducing the attachment capacity of NF-κB and
SP-1 (specificity protein) to DNA, thus allowing the downregulation of the matrix metalloproteinase (MMP)-9
enzyme [30]. These studies show that NF-κB has a key role
in cellular survival, and NF-κB inhibition is an essential
target in combating cancer. In this study, we found that
the highest NF-κB activation was obtained in the cisplatin
group, while the lowest NF-κB activation was achieved with
the combined use of lycopene and cisplatin. In other words,
additional inhibition of NF-κB activation by lycopene has
made the combination of lycopene and cisplatin treatment
even more effective.
As a transcription factor, Nrf2 was first described
by its capacity to bind to NF-E2/AP-1 repeat region in
the promoter region of the ß-globin gene [31] and has a
vital role in the induction of phase-II enzymes with key
detoxification and antioxidant features against reactive
oxygen radicals and potential carcinogens [10,32]. The
transcriptional up-regulation of these phase-II enzymes
are ensured via cis-acting DNA series that are titled
as antioxidant response element (ARE) located in the
promoter regions of these enzymes. Nrf2 is found in a
complex form with an inhibitory Keap1 protein in cellular
cytoplasm under normal conditions. After exposure
to oxidative stress, Nrf2 is separated from the complex
and passes to the nucleus to regulate the target genes by
binding to antioxidant response elements along with
other transcription factors [33]. Interestingly, Nrf2 has
been observed to possess quite different features from
each other depending on the stage of the carcinogenesis
process. For example, it functions as a tumor-suppressive
factor by binding to ARE and thus regulating cellular
detoxification and antioxidant response in the early stage
of pancreatic carcinogenesis [34]. The tumor may become
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even more aggressive as a result of the aberrant Nrf2
overexpression caused by Keap 1 mutation and silencing,
which are frequently observable in the later stage of the
above-mentioned carcinogenesis [35]. Carotenoids realize
their antioxidant features by increasing cytoprotective
enzyme levels that play an active role in cellular oxidative
stress response by enabling Nrf2 activation, a primary ARE
transcription factor [36]. In a study in which lycopene
was used for preventive strategies, it was observed that
lycopene reduced 12-dimethylbenz[a]anthracene-induced
hamster buccal pouch carcinogenesis by activating
detoxification pathways and ultimately inhibiting oxidative
stress [37]. In this study, we showed that the combination
treatment of lycopene and cisplatin increased Nrf2 more
than cisplatin treatment alone. Even though it is not quite
clear how lycopene induces the nuclear translocation
of Nrf2, a previous study showed that the interaction of
lycopene with cysteine residues of Keap1 resulted in Nrf2
activation by its release from the Keap1-Nrf2 complex
[38]. Likewise, the enhancement of the translocation of
Nrf2 to the nucleus by lycopene-derived metabolites via
affecting the upstream signal pathways is another possible
mechanism [19]. Due to key detoxifying and antioxidant
functions in the carcinogenesis process, evaluation of Nrf2
as a molecule that is attractive and possibly efficient for
new cancer treatment strategies appears to be an inevitable
approach and reality. Considering the dual function of Nrf2
in the carcinogenesis process, both Nrf2 induction and
Nrf2 inhibition might be targets of therapeutic medication
administration.
In this study, we revealed that lycopene acts
synergistically with cisplatin to prevent the growth of
cervical cancer cell lines. The findings of the present study
showed that cisplatin treatment is potentiated with lycopene
in HeLa cells by modulation of Bcl-2, Bax, NF-κB, and
Nrf2, which are important for cell survival and apoptosis.
Together, the results suggest that lycopene and concurrent
cisplatin chemotherapy could be used to improve the
treatment of cervical cancer by reducing cell survival and
increasing apoptosis. Therefore, this study can give a key
clue to the use of lycopene together with chemotherapeutic
agents. Future in vitro and animal studies are necessary
to examine the concurrent use of cisplatin and lycopene
in cervical cancer given the high rates of new cervical
cancer and related side effects of conventional treatment
modalities.
5. Conclusion
In conclusion, lycopene further strengthened the positive
effect of cisplatin on human cervical cancer cells by
regulating apoptosis proteins and transcription factors.
However, many preclinical and clinical studies are needed
to examine the effects of lycopene in the prevention and
treatment of cervical cancer.
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